United States: Federal Circuit Upholds Lyrica Patents

In a non-precedential decision issued February 6, 2014, the Federal Circuit affirmed a district court decision that upheld the four Orange Book listed patents for Pfizer's Lyrica® product. According to the court's rules, the non-precedential designation of Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. means that the panel determined that it did not add significantly to the body of law, but future panels may still look to it for "guidance or persuasive reasoning." As such, this decision upholding the Lyrica® patents illustrates the strength and breadth of patent protection that can be obtained for a new molecular entity.

The Patents at Issue

The patents at issue in the district court were U.S. Patent 6,197,819, U.S. Patent 5,563,175, U.S. Patent 6,001,876, and U.S. Reissue Patent 41,920 (a reissue of the '876 patent.). These patents are listed in the Orange Book for Pfizer's Lyrica® product, and this litigation was brought under 35 USC 271(e)(2)(A) after the defendants filed Abbreviated New Drug Applications (ANDAs) seeking FDA approval to market generic versions of Lyrica®.

According to the Federal Circuit decision, only two Lyrica® patents were in play for the appeal, the '819 patent and the RE '920 patent. From these, the court focused on claim 2 of the '819 patent:

2. 4-amino-3-(2-methylpropyl) butanoic acid, or a pharmaceutically acceptable salt thereof.

The prescribing information for Lyrica® identifies the active ingredient as Pregabalin and provides the chemical name

(S)-3-(aminomethyl)-5-methylhexanoic acid

which uses different nomenclature to identify the S-enantiomer of the compound recited in claim 2. The Federal Circuit also refers to the compound as "3-isobutylGABA."

The district court upheld the claims against enablement, written description, and obviousness challenges. As summarized by the Federal Circuit, because the defendants had stipulated to infringement, the district court issued an injunction that enjoined the defendants "from commercially manufacturing, using, offering for sale, or selling their proposed products" prior to the December 30, 2018 expiration date of the '819 patent.

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Prost, and joined by Chief Judge Rader and Judge Moore.

The Federal Circuit first addressed the district court's construction of claim 2 as generically reciting 3-isobutylGABA rather than specifying a racemic mixture of enantiomers, as argued by the defendants.

The Federal Circuit found that specification supported the district court's broader claim construction because the specification used the compound name generally, used the racemic designation in some instances, and used the enantiomeric designations in other instances. Because the racemic designation was not used in claim 2, the Federal Circuit agreed that "it should not be so limited." The court rejected the defendants' arguments that the report of data for racemic mixtures warranted construing claim 2 as being limited to racemic mixtures.

The enablement challenge was based on the assertion that, in order to support the generic claim construction, the specification "must teach a skilled artisan how to prepare every conceivable mixture of 3-isobutylGABA's enantiomers." The Federal Circuit rejected this line of argument, noting:

  • "[T]here is no requirement that a specification must 'disclose what is routine and well known in the art.'"
  • "[T]here is no dispute in the record that the co-inventors of the '819 patent were the first to create and claim the chemical compound 3-isobutylGABA.
  • "It is also undisputed that the parent application discloses the method for synthesizing the compound and states that the compound's 'enantiomers may be prepared or isolated by methods already well known in the art.'"
  • "[T]he PTO Examiner ... withdrew an enablement rejection ... during prosecution of the patent."

The Federal Circuit concluded:

Where a claim has been construed to cover a chemical compound, the specification is not deficient merely because it does not disclose how to prepare a particular form or mixture—among hundreds of possible permutations—of that compound. See In re Hogan, 559 F.2d 595, 606 (CCPA 1977) (noting that requiring such specific disclosures would "impose an impossible burden on inventors").

The Federal Circuit characterized the written description challenge as similar to the enablement challenge, being based on an alleged failure of the specification to disclose the various enantiomeric mixtures encompassed by claim 2. The Federal Circuit rejected this line of argument, noting:

[W]ritten description does not require inventors, at the time of their application for a patent, to reduce to practice and be in physical possession of every species (e.g., the S-enantiomer of 3-isobutylGABA) of a genus (3-isobutylGABA) claim. For claims to a chemical compound, an application satisfies the written description requirement when it details "relevant identifying characteristics" such that the compound can be distinguished from other compounds. In re Wallach, 378 F.3d 1330, 1333, 1335 (Fed. Cir. 2004).

Because the specification "disclosed the structure of 3-isobutylGABA as the preferred embodiment of the invention," "set forth in vitro and in vivo data for the compound," and "described a method of synthesizing the compound," the description was "sufficient for persons of ordinary skill in the art to recognize that the inventor invented what is claimed."

The obviousness challenge on appeal was based on the assertion that the district court failed to make the following factual findings:

  1. "Fish, Shashoua, and Colonge taught that 3-isopropylGABA and other homologous compounds may have anticonvulsant activity."
  2. "[O]ne of ordinary skill in the art would have expected 3-isobutylGABA to have anticonvulsant activity due to its structural similarities to 3-isopropylGABA."
  3. "[G]abapentin, a 3-alkylGABA compound in the prior art with demonstrated anticonvulsant efficacy, provided a motivation for persons skilled in the art to try other alkyl substituents at GABA's 3-position.

The Federal Circuit assessed the obviousness challenge under its "lead compound" framework. The Federal Circuit agreed with the district court that the evidence did not establish that either 3-isopropylGABA or gabapentin would have been selected as a lead compounds for anticonvulsant drugs, or that it would have been obvious to modify those compounds in the manner required to arrive at 3-isobutylGABA.

Thus, the Federal Circuit affirmed the district court's judgments that the patents were not invalid.

Developing New Drugs

New molecular entities may be the "gold standard" for new pharmaceutical products, but they also are the hardest to come by and may take the longest to develop. The FDA publishes annual lists of newly approved "new molecular entities (NMEs)" which it describes as "active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product," although some NMEs may be drugs that "contain active moieties that are closely related to active moieties in products that have previously been approved," such as biological products. Twenty-seven NMEs were approved in 2013, 39 were approved in 2012, and 30 were approved in 2011. In contrast, the FDA approved almost 100 New Drug Applications and Biologics License Applications in 2013 alone.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions